A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy

References

• HartungEFHistory of the use of colchicum and related medicaments in goutAnn Rheum Dis195413319020013198053
   PubMed Web of Science ®Google Scholar
• TerkeltaubRAColchicine update: 2008Semin Arthritis Rheum200938641141918973929
   PubMed Web of Science ®Google Scholar
• Ben-ChetritELevyMFamilial Mediterranean feverLancet199835191036596649500348
   PubMed Web of Science ®Google Scholar
• RavelliRBGigantBCurmiPAInsight into tubulin regulation from a complex with colchicine and a stathmin-like domainNature2004428697919820215014504
   PubMed Web of Science ®Google Scholar
• NielEScherrmannJMColchicine todayJoint Bone Spine200673667267817067838
   PubMed Web of Science ®Google Scholar
• SchwartzELAntivascular actions of microtubule-binding drugsClin Cancer Res20091582594260119351751
   PubMed Web of Science ®Google Scholar
• BhattacharyyaBPandaDGuptaSBanerjeeMAnti-mitotic activity of colchicine and the structural basis for its interaction with tubulinMed Res Rev200828115518317464966
   PubMed Web of Science ®Google Scholar
• PasquierEAndréNBraguerDTargeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatmentCurr Cancer Drug Targets20077656658117896922
   PubMed Web of Science ®Google Scholar
• TozerGMKanthouCBaguleyBCDisrupting tumour blood vesselsNat Rev Cancer20055642343515928673
   PubMed Web of Science ®Google Scholar
• KanthouCTozerGMTumour targeting by microtubule-depolymerizing vascular disrupting agentsExpert Opin Ther Targets200711111443145718028009
   PubMed Web of Science ®Google Scholar
• JordanMAWilsonLMicrotubules as a target for anticancer drugsNat Rev Cancer20044425326515057285
   PubMed Web of Science ®Google Scholar
• BaguleyBCHoldawayKMThomsenLLZhuangLZwiLJInhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanismEur J Cancer19912744824871827725
   PubMed Web of Science ®Google Scholar
• NiheiYSuzukiMOkanoAEvaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapyJpn J Cancer Res199990121387139510665658
   PubMedGoogle Scholar
• FinkelsteinYAksSEHutsonJRColchicine poisoning: the dark side of an ancient drugClin Toxicol (Phila)201048540741420586571
   PubMed Web of Science ®Google Scholar
• DickinsonMJunejaSHaematological toxicity of colchicineBr J Haematol2009146546519220282
   PubMedGoogle Scholar
• RautioJKumpulainenHHeimbachTProdrugs: design and clinical applicationsNat Rev Drug Discov20087325527018219308
   PubMed Web of Science ®Google Scholar
• QuinnFRNeimanZBeislerJAToxicity and quantitative structure-activity relationships of colchicinesJ Med Chem19812456366397241524
   PubMed Web of Science ®Google Scholar
• ZamoraJMPearceHLBeckWTPhysical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cellsMol Pharmacol19883344544623162758
   PubMed Web of Science ®Google Scholar
• WallaceSLOmokokuBErtelNHColchicine plasma levels: implications as to pharmacology and mechanism of actionAm J Med19704844434485444299
   PubMed Web of Science ®Google Scholar
• BagnatoJDEilersALHortonRAGrissomCBSynthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxinJ Org Chem200469268987899615609930
   PubMed Web of Science ®Google Scholar
• LagnouxDDarbreTSchmitzMLReymondJLInhibition of mitosis by glycopeptide dendrimer conjugates of colchicineChemistry200511133941395015861378
   PubMed Web of Science ®Google Scholar
• CrielaardBJvan der WalSLammersTLiposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kineticsEur J Pharm Sci Epub 2011 Sep 1
   Web of Science ®Google Scholar
• ParveenSSahooSKNanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugsClin Pharmacokinet2006451096598816984211
   PubMed Web of Science ®Google Scholar
• GreenwaldRBPendriABolikalDGilbertCWHighly water soluble taxol derivatives: 2′-polyethyleneglycol esters as potential prodrugsBioorg Med Chem Lett199442024652470
   Web of Science ®Google Scholar
• GreenwaldRBChoeYHMcGuireJConoverCDEffective drug delivery by PEGylated drug conjugatesAdv Drug Deliv Rev200355221725012564978
   PubMed Web of Science ®Google Scholar
• DennyWATumor-activated prodrugs – a new approach to cancer therapyCancer Invest200422460461915565818
   PubMed Web of Science ®Google Scholar
• ScudieroDAShoemakerRHPaullKDEvaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell linesCancer Res19884817482748333409223
   PubMed Web of Science ®Google Scholar
• Wet op de dierproeven. stb. 1977, 6. BWBR0003081; Article 9.
   Google Scholar
• European Treaty Series. 18 III 1986. ETS No. 123
   Google Scholar
• BrossiASharmaPNAtwellLBiological effects of modified colchicines. 2. Evaluation of catecholic colchicines, colchifolines, colchicide, and novel N-acyl- and N-aroyldeacetylcolchicinesJ Med Chem19832610136513696620299
   PubMed Web of Science ®Google Scholar
• NguyenTLMcGrathCHermoneARA common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approachJ Med Chem200548196107611616162011
   PubMed Web of Science ®Google Scholar
• FensMHHillKJIssaJLiposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanomaBr J Cancer20089981256126418797467
   PubMed Web of Science ®Google Scholar
• LammersTHenninkWEStormGTumour-targeted nanomedicines: principles and practiceBr J Cancer200899339239718648371
   PubMed Web of Science ®Google Scholar
• DanquahMKZhangXAMahatoRIExtravasation of polymeric nanomedicines across tumor vasculatureAdv Drug Deliv Rev201163862363921144874
   PubMed Web of Science ®Google Scholar
• YamadaTHosokawaMSatohTImmunohistochemistry with an antibody to human liver carboxylesterase in human brain tissuesBrain Res19946581–21631677834338
   PubMed Web of Science ®Google Scholar
• XieMYangDLiuLXueBYanBHuman and rodent carboxylesterases: Immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expressionDrug Metab Dispos200230554154711950785
   PubMed Web of Science ®Google Scholar
• RedinboMRPotterPMMammalian carboxylesterases: from drug targets to protein therapeuticsDrug Discov Today200510531332515749280
   PubMed Web of Science ®Google Scholar
• SatohTHosokawaMThe mammalian carboxylesterases: from molecules to functionsAnnu Rev Pharmacol Toxicol1998382572889597156
   PubMed Web of Science ®Google Scholar
• CrowJAHerringKLXieSBorazjaniAPotterPMRossMKInhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acidsBiochim Biophys Acta201018011314119761868
   PubMed Web of Science ®Google Scholar